Research programme: interferon-alpha variants - GenOdyssee

Drug Profile

Research programme: interferon-alpha variants - GenOdyssee

Alternative Names: GEA 0071; GEA 0092; GEA007.1; GEA009.2; INF71; Interferon-alpha variants research programme - GenOdyssee

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator GenOdyssee
  • Class Interferons
  • Mechanism of Action Immunostimulants; Interferon alpha stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Cancer; Hepatitis C; Influenza virus infections; Viral infections

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in France
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in Switzerland
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Hepatitis-C in France
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top